Browse SMPD2

Summary
SymbolSMPD2
Namesphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase)
Aliases nSMase; ISC1; NSMASE1; N-SMase; lyso-PAF-PLC; lyso-platelet-activating factor-phospholipase C; neutral sphin ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Multi-pass membrane protein.
Domain PF03372 Endonuclease/Exonuclease/phosphatase family
Function

Converts sphingomyelin to ceramide. Hydrolyze 1-acyl-2-lyso-sn-glycero-3-phosphocholine (lyso-PC) and 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine (lyso-platelet-activating factor). The physiological substrate seems to be Lyso-PAF.

> Gene Ontology
 
Biological Process GO:0006643 membrane lipid metabolic process
GO:0006644 phospholipid metabolic process
GO:0006664 glycolipid metabolic process
GO:0006665 sphingolipid metabolic process
GO:0006672 ceramide metabolic process
GO:0006684 sphingomyelin metabolic process
GO:0006687 glycosphingolipid metabolic process
GO:0009612 response to mechanical stimulus
GO:0019216 regulation of lipid metabolic process
GO:0030148 sphingolipid biosynthetic process
GO:0034248 regulation of cellular amide metabolic process
GO:0034250 positive regulation of cellular amide metabolic process
GO:0045834 positive regulation of lipid metabolic process
GO:0046467 membrane lipid biosynthetic process
GO:0046513 ceramide biosynthetic process
GO:0046889 positive regulation of lipid biosynthetic process
GO:0046890 regulation of lipid biosynthetic process
GO:0090153 regulation of sphingolipid biosynthetic process
GO:0090154 positive regulation of sphingolipid biosynthetic process
GO:0097164 ammonium ion metabolic process
GO:1903509 liposaccharide metabolic process
GO:1905038 regulation of membrane lipid metabolic process
GO:2000303 regulation of ceramide biosynthetic process
GO:2000304 positive regulation of ceramide biosynthetic process
Molecular Function GO:0004620 phospholipase activity
GO:0004767 sphingomyelin phosphodiesterase activity
GO:0008081 phosphoric diester hydrolase activity
GO:0016298 lipase activity
GO:0042578 phosphoric ester hydrolase activity
Cellular Component GO:0005901 caveola
GO:0044853 plasma membrane raft
GO:0045121 membrane raft
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04071 Sphingolipid signaling pathway
hsa00600 Sphingolipid metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-193681: Ceramide signalling
R-HSA-73887: Death Receptor Signalling
R-HSA-1660662: Glycosphingolipid metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-162582: Signal Transduction
R-HSA-166520: Signalling by NGF
R-HSA-428157: Sphingolipid metabolism
R-HSA-75893: TNF signaling
R-HSA-5626978: TNFR1-mediated ceramide production
R-HSA-193704: p75 NTR receptor-mediated signalling
Summary
SymbolSMPD2
Namesphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase)
Aliases nSMase; ISC1; NSMASE1; N-SMase; lyso-PAF-PLC; lyso-platelet-activating factor-phospholipase C; neutral sphin ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SMPD2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSMPD2
Namesphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase)
Aliases nSMase; ISC1; NSMASE1; N-SMase; lyso-PAF-PLC; lyso-platelet-activating factor-phospholipase C; neutral sphin ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SMPD2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSMPD2
Namesphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase)
Aliases nSMase; ISC1; NSMASE1; N-SMase; lyso-PAF-PLC; lyso-platelet-activating factor-phospholipase C; neutral sphin ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SMPD2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.9890.00637
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.4380.339
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.6680.523
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.540.0777
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.410.799
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7020.72
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.280.35
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.070.941
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5090.625
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1760.877
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1130.945
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.080.385
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SMPD2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSMPD2
Namesphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase)
Aliases nSMase; ISC1; NSMASE1; N-SMase; lyso-PAF-PLC; lyso-platelet-activating factor-phospholipase C; neutral sphin ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SMPD2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSMPD2
Namesphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase)
Aliases nSMase; ISC1; NSMASE1; N-SMase; lyso-PAF-PLC; lyso-platelet-activating factor-phospholipase C; neutral sphin ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SMPD2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SMPD2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSMPD2
Namesphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase)
Aliases nSMase; ISC1; NSMASE1; N-SMase; lyso-PAF-PLC; lyso-platelet-activating factor-phospholipase C; neutral sphin ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SMPD2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSMPD2
Namesphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase)
Aliases nSMase; ISC1; NSMASE1; N-SMase; lyso-PAF-PLC; lyso-platelet-activating factor-phospholipase C; neutral sphin ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SMPD2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSMPD2
Namesphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase)
Aliases nSMase; ISC1; NSMASE1; N-SMase; lyso-PAF-PLC; lyso-platelet-activating factor-phospholipase C; neutral sphin ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SMPD2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSMPD2
Namesphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase)
Aliases nSMase; ISC1; NSMASE1; N-SMase; lyso-PAF-PLC; lyso-platelet-activating factor-phospholipase C; neutral sphin ......
Chromosomal Location6q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SMPD2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.